Publications by authors named "Heinke Conrad"

Claim this Profile
A
A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes.
Nisit Khandelwal, Marco Breinig, Tobias Speck, Tillmann Michels, Christiane Kreutzer, Heinke Conrad

EMBO Mol Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.
Hans-Henning Schmidt, Yingzi Ge, Felix J Hartmann, Heinke Conrad, Felix Klug

Oncoimmunology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.
Mathias Witzens-Harig, Dirk Hose, Simone Jünger, Christina Pfirschke, Nisit Khandelwal, Heinke Conrad

Blood· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.
Daniel Sommermeyer, Heinke Conrad, Holger Krönig, Haike Gelfort, Helga Bernhard

Int J Cancer· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.
Holger Krönig, Kathrin Julia Falchner, Marcus Odendahl, Bettina Brackertz, Heinke Conrad

Int J Cancer· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.
Peter Meyerhuber, Heinke Conrad, Lilian Stärck, Matthias Leisegang, Dirk H Busch

J Mol Med (Berl)· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
Paola Di Bonito, Felicia Grasso, Stefania Mochi, Linda Petrone, Emanuele Fanales-Belasio, Heinke Conrad

Virology· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
Holger Krönig, Kathrin Hofer, Heinke Conrad, Philippe Guilaume, Julia Müller

Int J Cancer· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLs directed against HER2 specifically cross-react with HER3 and HER4.
Heinke Conrad, Kerstin Gebhard, Holger Krönig, Julia Neudorfer, Dirk H Busch

J Immunol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.
Helga Bernhard, Julia Neudorfer, Kerstin Gebhard, Heinke Conrad, Christine Hermann

Cancer Immunol Immunother· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C.
Matthias Löhn, Ulf Muzzulini, Kirill Essin, Suk-Ying Tsang, Torsten Kirsch, Heinke Conrad

J Hypertens· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis